What Three Encompass Health Insiders Selling Signals After a Rate Increase
Key Points
The transaction realized approximately $1.1 million at a weighted average price of $125.95 per share.
The executive reduced his direct common stock holdings by 11% through this open-market sale.
Darby maintains a direct position of 75,041 shares following the transaction.
- 10 stocks we like better than Encompass Health ›
John Patrick Darby, EVP and general counsel of Encompass Health Corporation (NYSE:EHC), sold 8,906 shares of common stock on August 10, according to an SEC Form 4 filing.
Transaction summary
| Metric | Value |
|---|---|
| Shares sold (directly held) | 8,906 |
| Transaction value | $1.1 million |
| Post-transaction shares (directly held) | 75,041 |
| Post-transaction value | $9.44 million |
Transaction value based on SEC Form 4 weighted average sale price ($125.95); post-transaction value based on the August 10 market close ($125.81).
Key questions
- How does this sale impact the executive's overall equity exposure?
The disposal of 8,906 shares accounted for 11% of the insider's direct common stock position, resulting in a remaining direct stake of 75,041 shares. - What was the execution range for the reported transaction?
The shares were sold in multiple transactions at prices ranging from $125.94 to $126.04, yielding a weighted average price of $125.95. - What is the financial profile of Encompass Health at the time of this trade?
The company, a provider of post-acute healthcare services, reported $6.2 billion in trailing-twelve-month revenue and $621.0 million in net income, supporting a market capitalization of $12.5 billion as of the August 10 market close. - Does the insider maintain other forms of beneficial ownership?
Total beneficial ownership is reported at 75,041 shares, which align with the executive's direct common stock holdings following this transaction.
Company Overview
| Metric | Value |
|---|---|
| Share Price (as of market close 2026-08-10) | $125.81 |
| Market Capitalization | $12.5 billion |
| Revenue (TTM) | $6.2 billion |
| Net Income (TTM) | $621.0 million |
Company Snapshot
- Encompass Health Corporation operates a diversified post-acute healthcare platform delivering inpatient rehabilitation services and home health and hospice care across the United States through both dedicated facilities and in-home settings.
- The company generates revenue through its two primary divisions: Inpatient Rehabilitation, which provides focused recovery treatment on an inpatient and outpatient basis, and Home Health and Hospice, which delivers care services directly to patients in their residences.
- Encompass Health serves patients transitioning from acute care settings, including those recovering from significant illnesses, surgeries, and injuries, with a customer base comprised of healthcare systems, insurance providers, and individual patients requiring post-acute care services.
Encompass Health Corporation is a leading operator in the post-acute healthcare sector, with a market capitalization of $12.5 billion and TTM revenues of $6.2 billion, positioning it as a significant provider of rehabilitation and home-based care services. The company's diversified business model across inpatient facilities and home health services provides revenue stability and exposure to the growing demand for post-acute care driven by an aging population and the shift toward value-based care delivery. With over 42,000 employees and a strong net income margin of approximately 10% on TTM revenues, Encompass Health maintains operational scale and profitability in a fragmented market characterized by consolidation opportunities.
What this transaction means for investors
Darby wasn't alone among insiders selling shares after a strong earnings report lifted the stock, and the quarter they sold into had a specific tailwind worth noting. Beyond the 10% revenue growth and the raised guidance, Encompass benefits from a coming Medicare rate increase, the firm noted on its latest earnings call. Federal regulators finalized a rule in late July lifting payments for inpatient rehabilitation by about 2.3% starting in October, and because Medicare covers a large share of Encompass patients, that adjustment flows fairly directly toward its results, and it was part of why management raised its outlook for the second time this year.
The reimbursement backdrop is the real thing for shareholders to track, more than three insiders trimming after a rally. Encompass grows by adding hospital capacity into steady demand, but its pricing leans on government rates, so a favorable Medicare update helps and an unfavorable one would sting.
Should you buy stock in Encompass Health right now?
Before you buy stock in Encompass Health, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Encompass Health wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $421,511!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,381,960!*
Now, it’s worth noting Stock Advisor’s total average return is 981% — a market-crushing outperformance compared to 216% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
See the 10 stocks »
*Stock Advisor returns as of August 16, 2026.
Jonathan Ponciano has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.
Recommended Articles
